{"nctId":"NCT01682720","briefTitle":"Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection","startDateStruct":{"date":"2012-09"},"conditions":["Hepatitis C"],"count":421,"armGroups":[{"label":"Placebo 12 Weeks (GT2/3)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to match SOF","Drug: Placebo to match RBV"]},{"label":"SOF 12 Weeks (GT2/3)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF 24 Weeks (GT3)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"SOF","otherNames":["SovaldiÂ®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]},{"name":"Placebo to match SOF","otherNames":[]},{"name":"Placebo to match RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\> 18 with chronic genotype 2 or 3 HCV infection\n* HCV RNA \\> 10,000 IU/mL at screening\n* Subjects must be treatment naive or treatment experienced\n* Presence or absence of cirrhosis; a liver biopsy may be required\n* Healthy according to medical history and physical examination with the exception of HCV diagnosis\n* Agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication\n\nExclusion Criteria:\n\n* Prior use of any other inhibitor of the HCV NS5B Polymerase\n* History of any other clinically significant chronic liver disease\n* Evidence of or history of decompensated liver disease\n* HIV or chronic hepatitis B virus (HBV) infection\n* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)\n* Chronic use of immunosuppressive agents or immunomodulatory agents\n* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study or not be in the best interest of the subject in the opinion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ, ie, \\< 25 IU/mL) 12 weeks following the last dose of study drug. Data for this outcome measure was not collected for the Placebo 12 Weeks (GT2/3) group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"85.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events Leading to Permanent Discontinuation of Study Drug(s)","description":"The percentage of participants experiencing an adverse event leading to permanent discontinuation of study drug(s) was analyzed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 was defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively. Data for this outcome measure was not collected for the Placebo 12 Weeks (GT2/3) group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"84.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse","description":"Viral breakthrough was defined as having confirmed detectable HCV RNA levels (HCV RNA \\> LLOQ) after having previously had undetectable HCV RNA levels (HCV RNA \\< LLOQ) while on treatment.\n\nViral relapse was defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) at end of treatment, but did not achieve an SVR.\n\nData for this outcome measure was not collected for the Placebo 12 Weeks (GT2/3) group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"54.5","spread":null},{"groupId":"OG002","value":"14.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":85},"commonTop":["Headache","Fatigue","Pruritus","Asthenia","Nausea"]}}}